Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Evaluation Of Cd56 And Cd117 Double-positivity As A Predictor Of Poor Prognosis In Multiple Myeloma Patients: A Retrospective Analysis

Evaluation of CD56 and CD117 Double-Positivity as a Predictor of Poor Prognosis in Multiple Myeloma Patients: A Retrospective Analysis

Hakan Keski1, Selim Merdan2, Itır Ebru Zemheri3

  • 1University of Health Sciences Türkiye, Ümraniye Training and Research Hospital, Clinic of Hematology, İstanbul, Türkiye

Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology
|October 8, 2024

Related Experiment Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.5K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K
Discrimination of Seven Immune Cell Subsets by Two-fluorochrome Flow Cytometry
10:58

Discrimination of Seven Immune Cell Subsets by Two-fluorochrome Flow Cytometry

Published on: March 5, 2019

13.8K

View abstract on PubMed

Summary
This summary is machine-generated.

Multiple myeloma (MM) patients with both CD56 and CD117 expression have a poorer prognosis. This study clarifies the prognostic implications of these markers for MM survival outcomes.

Area of Science:

  • Hematologic Malignancies
  • Immunophenotyping in Oncology

Background:

  • Multiple myeloma (MM) is a challenging hematologic malignancy with variable prognoses.
  • Accurate risk stratification and prognostic assessment are crucial for effective MM patient management.
  • The prognostic significance of CD56 and CD117 expression in MM remains incompletely understood.

Purpose of the Study:

  • To investigate the prognostic implications of CD56 and CD117 expression in multiple myeloma patients.
  • To analyze the association of these markers with clinical features and survival outcomes.
  • To stratify MM patients based on CD56 and CD117 immunophenotypes for prognostic assessment.

Main Methods:

  • Retrospective single-center study of 168 adult MM patients.
  • Analysis of CD56 and CD117 expression levels via immunophenotyping.
Keywords:
CD117CD56Multiple myelomaCytogenetic abnormalities

Related Experiment Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.5K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K
Discrimination of Seven Immune Cell Subsets by Two-fluorochrome Flow Cytometry
10:58

Discrimination of Seven Immune Cell Subsets by Two-fluorochrome Flow Cytometry

Published on: March 5, 2019

13.8K
  • Classification of patients into four groups: CD56+CD117-, CD56-CD117+, CD56+CD117+, and CD56-CD117-.
  • Comparison of groups based on clinical characteristics, treatment response (overall response rate - ORR), and survival outcomes (overall survival - OS).

    • Main Results:

    • CD56 and CD117 double positivity was observed in 21.4% of patients.
    • Double-positive patients exhibited significantly higher cytogenetic risk and lower ORR (p<0.001).
    • CD56 positivity correlated with lower ORR and OS (p=0.017, p=0.004).
    • CD56+ and CD117+ patients had higher mortality rates compared to double-negative patients (p<0.001, p=0.002).
    • High cytogenetic risk independently predicted shorter OS (p>0.001).

    Conclusions:

    • MM patients co-expressing CD56 and CD117 demonstrate a poorer prognosis.
    • These immunophenotypic markers are associated with lower overall response rates, shorter overall survival, and increased mortality.
    • CD56 and CD117 expression, alongside cytogenetic risk, are important prognostic factors in multiple myeloma.
    Survival